Dong‑Hoon Lee

Person

Last mentioned: 5d ago

Stories mentioning Dong‑Hoon Lee 1

pharma Very Bullish

Insilico's $2.5B AI CNS Biobucks Deal With SK Bio Sets APAC Record

In the largest Asia‑Pacific licensing deal for Insilico Medicine, the AI‑first biotech secured up to $2.5 billion in milestones plus royalties from South Korea's SK Biopharmaceuticals, a CNS powerhouse, to co‑develop next‑generation neuroimmune therapies. The heavily back‑ended structure reflects industry‑standard risk‑sharing, with Insilico taking $18M up front and SK steering commercialization, underscoring a growing appetite for AI‑discovered assets in big pharma pipelines.

2 sources

About Dong‑Hoon Lee coverage

This page surfaces every story mentioning Dong‑Hoon Lee across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.

Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.

What you seeWhat it tells you
Story countNumber of distinct stories where Dong‑Hoon Lee was a primary or referenced actor.
Recency clusteringWhether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc).
Sentiment distributionAggregate sentiment of the stories mentioning this entity, weighted by impact score.
Cross-niche linksWhen the same entity surfaces in our sibling networks, we link to those views to enrich context.